"Patience is a Super Power" - "The Money is in the waiting"
Showing posts with label gene editing. Show all posts
Showing posts with label gene editing. Show all posts

Tuesday, November 17, 2026

An Alternative to an Uncertain AI Trade - medicine and, in particular, Genetics

 


Investment Note: Gene editing in focus

Why I like BEAM, CRSP and NTLA 

The Next Medical Revolution — and an Alternative to an Uncertain AI Trade

November 16, 2026 | Investment horizon: 2027–2028

A potentially historic turning point in medicine

Over the past several years, much of the investment world's attention and capital has been concentrated on artificial intelligence, semiconductors, data centres and the enormous infrastructure required to support them.

While AI will undoubtedly remain an important technological revolution, I believe another transformation is unfolding that may ultimately prove just as significant to humanity: the ability to treat, correct and potentially cure serious diseases by editing human genes.

This is no longer simply theoretical science.

Three publicly traded biotechnology companies—Beam Therapeutics (NASDAQ: BEAM), CRISPR Therapeutics (NASDAQ: CRSP) and Intellia Therapeutics (NASDAQ: NTLA)—are approaching important milestones that could help move genetic medicine from specialized experimental treatments toward broader commercial adoption.

Two years ago I took positions in all three, with BEAM as my principal investment, CRSP as the more commercially established complement and NTLA as the higher-risk, potentially higher-reward opportunity. I exited those positions in favor of the Ai buildout trade.  I am now considering entering positions again.

1. Beam Therapeutics (BEAM): My first choice

Beam is developing base editing, a technology designed to make precise changes to individual DNA letters without requiring the conventional double-strand DNA cuts associated with earlier CRISPR approaches.

This potentially provides a more precise way of addressing the genetic causes of disease.

On November 10, 2026, Beam announced positive pivotal results for risto-cel, its investigational sickle-cell treatment. The trial met its primary efficacy and safety endpoints, and the company expects to submit its FDA application as early as year-end 2026.

Equally important is BEAM-302, which aims to correct the underlying genetic defect responsible for alpha-1 antitrypsin deficiency, a serious inherited condition affecting the lungs and liver. Early clinical evidence suggests the treatment is producing the intended biological effects.

Beam reported approximately US$1 billion in cash and marketable securities at September 30, 2026. Its projected funding runway extends into mid-2029, including a conditional financing draw.

Why I am interested: Beam combines a potentially revolutionary technology platform with increasingly convincing clinical evidence, several development programs and sufficient financial resources to pursue major milestones.

I also believe its proprietary technology could make it an attractive strategic acquisition candidate for a larger pharmaceutical company seeking to expand into genetic medicine.

2. CRISPR Therapeutics (CRSP): The commercial validation

CRISPR Therapeutics has already achieved something that many biotechnology companies spend decades pursuing: bringing a gene-editing medicine to market.

Its CASGEVY treatment, developed with Vertex Pharmaceuticals, is approved for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia.

CASGEVY generated approximately US$99 million in product revenue during the third quarter of 2026, representing 30% sequential growth. More than 750 patients worldwide had initiated treatment.

CRSP is also developing CTX310, an investigational in-body gene-editing treatment targeting serious lipid disorders. If successful, its applications could extend beyond rare genetic diseases into much larger cardiovascular markets.

The company reported approximately US$2.28 billion in cash and marketable securities, although part of that balance reflects convertible-debt financing.

Why I am interested: CRSP provides tangible evidence that gene-editing medicine can become a commercial business. Its substantial financial resources, expanding pipeline and relationship with Vertex strengthen the long-term investment case.

A potential acquisition by Vertex or another pharmaceutical company is conceivable, although existing partnerships may reduce the need for a full takeover.

3. Intellia Therapeutics (NTLA): The potentially historic catalyst

Intellia may be approaching one of the most consequential regulatory milestones in genetic medicine.

Its investigational lonvo-z treatment is designed to provide a one-time therapy for hereditary angioedema, a serious disorder that causes recurrent swelling attacks.

In Phase 3 testing, the treatment reduced attacks by approximately 87% compared with placebo over six months.

The FDA has accepted Intellia's application, with a target decision date of March 10, 2027.

If approved, lonvo-z could become the world's first commercially approved treatment that uses CRISPR to edit genes directly inside the human body.

That distinction is enormously important. Rather than removing cells, modifying them in a laboratory and returning them to the patient, in-body gene editing offers the prospect of simpler treatment delivery for certain diseases.

Intellia also has a strategic relationship with Regeneron Pharmaceuticals.

Why I am interested: NTLA offers the possibility of a major regulatory and commercial breakthrough within months. Its comparatively smaller market capitalization could make successful commercialization particularly meaningful to shareholders.

However, the company has experienced safety concerns in a separate gene-editing program, and FDA approval is not assured. I would therefore treat NTLA as the smallest and most speculative of the three investments.

4. Why Big Pharma could become interested

Large pharmaceutical companies face a continuing challenge: important medicines eventually lose patent protection, exposing billions of dollars in annual revenue to generic and biosimilar competition.

Acquiring innovative biotechnology companies is one way to replenish their development pipelines and obtain technologies that could underpin future generations of treatments.

Gene editing is especially attractive because it offers the possibility of treating diseases at their genetic source rather than managing symptoms indefinitely.

I see three potential reasons for acquisition interest:

  • Proprietary technology: A successful gene-editing platform could generate numerous future medicines, making the technology itself strategically valuable.

  • Clinical and regulatory validation: As treatments demonstrate efficacy and obtain approvals, some of the uncertainty facing potential acquirers diminishes.

  • Access to new markets: Successful gene-editing therapies for cardiovascular, metabolic and other widespread diseases could create much larger commercial opportunities than today's initial rare-disease applications.

Beam's base-editing platform, CRSP's approved treatment and Intellia's in-body editing capabilities each represent different strategic opportunities.

Existing relationships involving Pfizer, Eli Lilly, Vertex and Regeneron illustrate the pharmaceutical industry's interest in these technologies.

I consider Beam the most interesting potential acquisition candidate, followed by Intellia and CRISPR Therapeutics. This is a judgment about strategic attractiveness, not evidence of current acquisition discussions.

Importantly, my investment thesis does not depend on a takeover. These businesses must ultimately create value through successful medicines, commercialization and sustainable economics.

5. Why consider these investments now, amid the Nvidia controversy?

The timing of this opportunity is particularly interesting.

Nvidia's co-founder Jensen Huang resigned in November following reports concerning his personal conduct and allegations involving a suspected foreign-intelligence connection.

The controversy has raised questions about corporate governance, leadership succession and Nvidia's future strategic direction. The intelligence-related allegations remain unproven, and Nvidia has stated that it has no reason to believe company secrets were compromised.

More broadly, investors are increasingly questioning the financial structure supporting the AI infrastructure boom.

Enormous capital commitments, complex financing arrangements, circular investment relationships and uncertainty about future returns on AI spending have created concern about whether the market has become excessively dependent on a relatively small number of technology companies.

I do not believe this necessarily means the AI revolution is ending.

However, a temporary correction in AI-related equities could encourage investors to reconsider where the next major technological and commercial opportunities will emerge.

Genetic medicine offers a compelling alternative.

Unlike an AI infrastructure investment, whose immediate financial prospects may depend on continued data-centre construction and semiconductor spending, biotechnology companies can experience substantial valuation changes following successful clinical trials, FDA approvals and commercial adoption.

Their catalysts are different.

This does not make biotechnology immune to market corrections. Smaller biotechnology stocks are often highly sensitive to interest rates, liquidity and investor risk appetite. A broad technology selloff could initially drag biotechnology shares lower as well.

Nevertheless, over a two-year horizon, I believe successful genetic-medicine companies could develop investment momentum based on their own medical and commercial achievements, rather than the trajectory of AI infrastructure spending.

6. My proposed investment approach

I favour taking positions gradually rather than attempting to predict the precise bottom in any of these stocks.

Within a dedicated speculative genetic-medicine allocation, my preferred weighting would be:

CompanyAllocationInvestment role
BEAM45%Primary technology and growth position
CRSP40%Commercial validation and broader pipeline
NTLA15%Higher-risk regulatory and takeover optionality

I would initially establish partial positions and retain capital to take advantage of market weakness or additional clinical evidence.

There are meaningful risks: disappointing trial results, regulatory setbacks, unexpected safety problems, expensive commercialization, dilution and prolonged operating losses. The three companies also share substantial exposure to the same emerging field, making this a concentrated investment rather than a diversified healthcare portfolio.

7. My investment conclusion

I believe we may be approaching an important inflection point in genetic medicine.

For decades, many inherited diseases could be managed but not fundamentally corrected. Today, companies such as Beam, CRISPR Therapeutics and Intellia are demonstrating that this limitation may increasingly be overcome.

The medical implications are extraordinary, and the commercial implications could be substantial.

At the same time, uncertainty surrounding Nvidia, the financing of the AI infrastructure boom and the concentration of market capital in a handful of technology companies makes it sensible to investigate other sources of long-term growth.

My interest in BEAM, CRSP and NTLA is therefore based on three converging opportunities:

  1. The transition of gene editing from experimental science toward commercial medicine.

  2. The possibility that major pharmaceutical companies will increasingly seek to acquire or partner with developers of proprietary genetic technologies.

  3. The opportunity to diversify growth capital into a potentially transformative industry whose fundamental catalysts differ from those driving the AI infrastructure trade.

I regard BEAM as my first choice, CRSP as my second and NTLA as a smaller, higher-risk third position.

The next 24 months could prove particularly important as regulatory decisions, clinical results and commercialization provide clearer evidence of which companies will become leaders in genetic medicine.

The opportunity is substantial, but success is not assured. I would pursue these investments with a multi-year horizon, disciplined position sizing and a willingness to reassess the thesis as clinical and financial evidence develops.

The central investment proposition is simple: while markets debate the next phase of artificial intelligence, a revolution in the treatment of human disease may already be entering its commercial era.

Investment research note — November 16, 2026. This reflects a speculative investment thesis, not guaranteed returns or confirmed takeover interest.

Research supporting the note

The principal clinical and financial information comes from the companies' November 2026 disclosures: Beam's pivotal clinical results, CRISPR Therapeutics' Q3 results and Intellia's Q3 results.

Beam Therapeutics+2

For the Nvidia discussion, Reuters reports Huang's resignation and the related governance concerns, while distinguishing allegations from established wrongdoing. Reuters also identifies investor scrutiny of AI financing arrangements and Nvidia's leadership transition

Ed Note:

I would not disregard the possible takeover value of these three as their cutting edge technology develops and commercializes. Big Pharma is always on the lookout for such tasty morsels!

Tuesday, June 25, 2024

Going forward, how viable is Beam Therapeutics in the BioTech market?

 




Fr: ChatGPT

Beam Therapeutics appears to be a viable biotechnology company, with several strengths that contribute to its potential:

  1. Financial Stability and Future Prospects: Beam Therapeutics has demonstrated strong financial management with a substantial increase in cash reserves, which were reported to be $1.2 billion at the end of 2023. This financial position is expected to fund the company's operations into 2027, showing a robust capability to sustain its long-term research and development plans​ (Beam Therapeutics)​.

  2. Advanced Gene Editing Technology: Beam specializes in base editing technology, which allows for precise, predictable, and efficient changes at specific DNA sequences without making double-stranded breaks. This technology has broad applications in developing genetic medicines for a variety of diseases​ (Beam Therapeutics)​​ (markets.businessinsider.com)​.

  3. Strategic Partnerships and Pipeline Development: The company has formed strategic alliances, such as the significant partnership with Eli Lilly, which includes substantial financial backing and collaborative opportunities in cardiovascular disease therapies. This alliance alone could bring up to $600 million in future development payments to Beam​ (markets.businessinsider.com)​.

  4. Clinical Trials and Research Focus: Beam is actively advancing multiple clinical trials, including a Phase 1/2 trial for a CAR-T therapy candidate and other in vivo gene editing programs targeting both rare genetic and more common disorders. This active pipeline underlines the company's commitment to bringing new therapies to market​ (markets.businessinsider.com)​​ (Beam Therapeutics)​.

  5. Manufacturing and Operational Expansion: The company is also expanding its manufacturing capabilities, having initiated GMP operations in its North Carolina facility, which supports both current and future therapy production needs​ (Beam Therapeutics)​.

  6. Institutional Investors:

    Strong institutional backing indicates a high level of confidence in Beam Therapeutics' future potential and stability, reflecting its position in the biotechnology and genetic editing fields.

  7. Ownership: Beam Therapeutics is heavily supported by institutional investors, with about 99.68% of its stock owned by these entities. Some of the largest institutional shareholders include FMR LLC, Vanguard Group Inc., BlackRock Inc., and State Street Corp. Notably, FMR LLC holds a significant portion of the shares, representing a substantial stake in the company. Other major investors include Ark Investment Management LLC and Farallon Capital Management LLC, highlighting a robust interest from high-profile investment firms​ (MarketBeat)​​ (WallStreetZen)​.

Competition:

Beam Therapeutics is positioned in a competitive field of biotechnology companies focusing on precision genetic medicines. 

Its main competitors include Kymera Therapeutics, Intellia Therapeutics, Replimune Group, Editas Medicine, Sangamo Therapeutics, Repligen, Exelixis, Halozyme Therapeutics, Revolution Medicines, and ImmunityBio. These companies are all part of the medical sector, focusing on similar technologies and therapeutic approaches​ (MarketBeat)​.

In terms of financial performance and stock metrics, Beam Therapeutics stands out with a higher revenue compared to many of its peers, but also exhibits higher volatility in its stock price. Notably, Beam has a significant institutional ownership, which suggests confidence from large investors about its future growth prospects. However, it faces strong competition from companies like Kymera Therapeutics, which has been rated slightly higher in terms of analyst consensus and market sentiment​ (MarketBeat)​.

Beam Therapeutics uses advanced CRISPR-based gene editing technology, which positions it at the forefront of gene editing innovation. Despite its strong technological base and institutional backing, the company's stock trades at a relatively lower price-to-earnings ratio compared to Kymera, indicating potential undervaluation or differing market perceptions about its growth potential 

Given these factors, Beam Therapeutics shows significant promise and viability as a biotech company focused on developing precision genetic medicines. However, it's essential for investors to consider the inherent risks associated with the biotech industry, including regulatory hurdles and the technical challenges of developing new medical treatments.

Pfizer is actively using artificial intelligence (AI) and machine learning (ML) to enhance its drug development processes.





Thursday, June 20, 2024

Illumina's strong market position in the genomics and life sciences sectors, positive return on equity, recent insider buying and Ai applications signal confidence in its future​

 Illumina Inc. (NASDAQ: ILMN), has several positive indicators for the company's prospects going forward.

  1. Analyst Ratings and Price Targets: The consensus rating among analysts is generally favorable. According to Stock Analysis, out of 19 analysts, the average rating is a "Buy" with a 12-month average price target of $158.89, representing a potential upside of approximately 45.68% from its current price of around $109.10​ (Stock Analysis)​​ (Stock Analysis)​. Specific price targets range from a low of $100 to a high of $253​ (Stock Analysis)​.

  2. Recent Developments: Illumina has been actively enhancing its product offerings, such as integrating new chemistry across its sequencers, which aims to improve quality and speed at a lower cost​ (Stock Analysis)​. Additionally, the company is in the process of spinning off Grail, its cancer test maker subsidiary, which is expected to focus Illumina more on its core sequencing and genomics technologies​ (Stock Analysis)​.

  3. Financial Performance and Forecasts: Despite a slight decline in revenue year-over-year, Illumina's revenue forecast for 2024 is positive, with expected growth of 2.15% to $4.60 billion and further growth projected for subsequent years​ (Stock Analysis)​. Analysts also forecast significant EPS growth from $0.74 in 2023 to $2.57 in 2024​ (Stock Analysis)​.

  4. Pros and Cons:

    • Pros: Illumina's strong market position in the genomics and life sciences sectors, positive return on equity, and recent insider buying signal confidence in its future​ (MarketBeat)​.
    • Cons: The company's negative net margin of 28.71%, mixed analyst ratings, and financial leverage could pose challenges. Additionally, fluctuations in stock price may concern short-term investors​ (MarketBeat)​.

In summary, while there are some financial and operational challenges, the general outlook for Illumina is positive with a consensus among analysts that the stock is likely to perform well over the next year. However, investors should be mindful of the mixed ratings and financial leverage when making investment decisions.

Ai applications

Illumina is leveraging artificial intelligence (AI) to enhance its genomic sequencing technology and broaden its application in various fields. Here are some key ways in which Illumina is applying AI:

  1. Data Analysis and Interpretation:

    • AI Algorithms: Illumina uses AI algorithms to analyze vast amounts of genomic data more quickly and accurately. This includes identifying genetic variants and interpreting their significance in the context of diseases.
    • Variant Calling and Annotation: AI helps in the accurate calling of genetic variants from sequencing data and annotating these variants to understand their potential impact on health.
  2. Machine Learning for Sequencing Efficiency:

    • Improving Sequencing Accuracy: Machine learning models are used to improve the accuracy and reliability of sequencing reads, reducing errors and enhancing the quality of the output data.
    • Optimization of Sequencing Protocols: AI optimizes sequencing protocols, reducing the time and cost associated with sequencing projects.
  3. Personalized Medicine:

    • Predictive Modeling: AI is used to create predictive models that can forecast an individual’s risk of developing certain diseases based on their genetic profile. This is a step towards personalized medicine, where treatment can be tailored to an individual’s genetic makeup.
    • Drug Development: By analyzing genomic data, AI helps in identifying potential drug targets and biomarkers, accelerating the drug development process.
  4. Clinical Applications:

    • Diagnostics: AI aids in the development of diagnostic tests by identifying genetic markers associated with diseases. This is particularly useful in oncology, where genomic data can help in the early detection of cancer.
    • Patient Stratification: AI is used to stratify patients based on their genetic data, which helps in designing more effective clinical trials and treatments.
  5. Automation and Workflow Improvement:

    • Automated Data Processing: AI automates the processing of sequencing data, reducing manual intervention and increasing throughput.
    • Workflow Optimization: AI-driven tools optimize laboratory workflows, ensuring efficient use of resources and reducing turnaround times.
  6. Population Genomics:

    • Large-Scale Genomic Studies: AI facilitates the analysis of data from large-scale genomic studies, such as population genomics projects, by identifying patterns and correlations within vast datasets.
  7. Integration with Other Technologies:

    • Multi-Omics Data Integration: AI integrates genomic data with other omics data (e.g., transcriptomics, proteomics) to provide a comprehensive understanding of biological systems.
    • Cross-Platform Analytics: AI enables cross-platform analytics, integrating data from different sequencing platforms and technologies to provide unified insights.

By incorporating AI into these various aspects of its technology and operations, Illumina is enhancing the capabilities of its genomic sequencing tools, making them more efficient, accurate, and applicable to a wide range of scientific and medical challenges.

Update July 1st, Analyst Notes:  RBC Capital reiterated it's "Outperform" rating on $ILMN with a price target of $242 - Today's price $105

Disclosure: the writer has a position in ILMN

In Bio Science, there is a race for better Gene sequencing and genomics technology!

Pfizer is actively using artificial intelligence (AI) and machine learning (ML) to enhance its drug development processes.



Friday, May 10, 2024

Can two small caps become the kings of synthetic biology? Only time will tell!

 Both Twist Biosciences and Ginkgo Bioworks are prominent players 

in the field of  Synthetic biology, but they have different focuses and strengths.

Let’s take a closer look at each company: Twist Biosciences: Core Focus: Twist Biosciences specializes in high-quality synthetic DNA production using its Silicon Platform. They offer custom DNA synthesis services to researchers, biotech companies, and other organizations. Technology: Their Silicon Based DNA synthesis platform allows for efficient and precise DNA manufacturing. Applications: Twist’s DNA products are used in various applications, including Gene Editing, vaccine development, Drug discovery, and more. Collaboration with Ginkgo: Twist has a collaboration with Ginkgo Bioworks, which includes a four-year supply agreement. Ginkgo purchases products from Twist, allowing them to test proteins and develop diverse solutions across multiple industries. Recent Deal: In 2022, Twist agreed to supply at least 100 million base pairs of synthetic DNA to Ginkgo over a one-year period for engineering prototype organisms. Ginkgo Bioworks: Core Focus: Ginkgo is a horizontal platform for cell programming. They aim to make programming cells as easy as programming computers. Technology: Ginkgo’s platform enables biotechnology applications across various markets, including food, agriculture, industrial chemicals, and pharmaceuticals. Applications: Ginkgo focuses on organism design and engineering, optimization, and other synthetic biology services. Collaboration with Twist: Ginkgo collaborates with Twist to secure high volumes of DNA. They have ordered approximately one billion base pairs of synthetic DNA from Twist over the past four years for various programs. Expansion Plans: Ginkgo’s collaboration with Twist aims to fuel their expansion plans in the synthetic biology field. In summary, both companies contribute significantly to the synthetic biology ecosystem, but their expertise lies in different areas.
Twist excels in DNA synthesis, while Ginkgo focuses on cell programming and organism engineering.
The collaboration between these two organizations demonstrates their commitment to advancing the field of synthetic biology.

Foot notes:

Most recently Googles "Deep Mind" Ai has been used in combination with Synbio, cell programming and gene editing, to further the advancement in cooperation with a number of companies.

With the deep, data set of Alphabet, combined with Deep Mind's cutting edge Ai, and the massive data bank that is the human DNA, medicine and medical disciplines will benefit immensely from what is coming! And, so will human kind!